152 related articles for article (PubMed ID: 37516697)
1. The Mediator Complex Subunit 12 (MED-12) Gene and Uterine Fibroids: a Systematic Review.
Amendola ILS; Spann M; Segars J; Singh B
Reprod Sci; 2024 Feb; 31(2):291-308. PubMed ID: 37516697
[TBL] [Abstract][Full Text] [Related]
2. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
3. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
4. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids.
Halder SK; Laknaur A; Miller J; Layman LC; Diamond M; Al-Hendy A
Mol Genet Genomics; 2015 Apr; 290(2):505-11. PubMed ID: 25325994
[TBL] [Abstract][Full Text] [Related]
5. The Epidemiology and Genetics of Uterine Leiomyoma.
Styer AK; Rueda BR
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():3-12. PubMed ID: 26725703
[TBL] [Abstract][Full Text] [Related]
6. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
Park MJ; Shen H; Kim NH; Gao F; Failor C; Knudtson JF; McLaughlin J; Halder SK; Heikkinen TA; Vahteristo P; Al-Hendy A; Schenken RS; Boyer TG
J Clin Endocrinol Metab; 2018 Nov; 103(11):4283-4292. PubMed ID: 30099503
[TBL] [Abstract][Full Text] [Related]
7. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
9. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
10. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
11. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
[TBL] [Abstract][Full Text] [Related]
12. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
13. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Analysis Identifies Tenascin-C Expression Is Upregulated in Uterine Fibroids.
Jamaluddin MFB; Nagendra PB; Nahar P; Oldmeadow C; Tanwar PS
Reprod Sci; 2019 Apr; 26(4):476-486. PubMed ID: 29730954
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of the mediator kinase-dependent myometrial stem cell phosphoproteome.
Barron L; Khadka S; Schenken R; He L; Blenis J; Blagg J; Chen SF; Tsai KL; Boyer TG
F S Sci; 2021 Nov; 2(4):383-395. PubMed ID: 35559861
[TBL] [Abstract][Full Text] [Related]
16. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic and enhancer dysregulation in uterine leiomyomas.
Mlodawska OW; Saini P; Parker JB; Wei JJ; Bulun SE; Simon MA; Chakravarti D
Hum Reprod Update; 2022 Jun; 28(4):518-547. PubMed ID: 35199155
[TBL] [Abstract][Full Text] [Related]
19. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
[TBL] [Abstract][Full Text] [Related]
20. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
